Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, CYTK, EIKN, RLAY, XENE, and represent 98.07% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 3 stocks: CYTK (+$18M), CRNX (+$5.6M), RLAY.
  • Started 1 new stock position in CRNX.
  • Reduced shares in these 3 stocks: LYEL (-$16M), ALEC (-$8.4M), MAZE.
  • Sold out of its positions in ALEC, LYEL, MAZE.
  • Foresite Capital Management IV was a net seller of stock by $-797k.
  • Foresite Capital Management IV has $290M in assets under management (AUM), dropping by 22.38%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 6 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 57.0 $165M 4.8M 34.58
 View chart
Cytokinetics (CYTK) 21.0 $61M +42% 715k 85.19
 View chart
Eikon Therapeutics (EIKN) 8.7 $25M 1.9M 13.05
 View chart
Relay Therapeutics (RLAY) 8.1 $23M +25% 1.3M 18.71
 View chart
Xenon Pharmaceuticals (XENE) 3.3 $9.7M 160k 60.36
 View chart
Crinetics Pharmaceuticals In (CRNX) 1.9 $5.6M NEW 150k 37.42
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings